Drug trial aims to calm deadly COVID-19 immune overreaction
NCT ID NCT04412772
Summary
This study tested whether the drug tocilizumab could help hospitalized adults with severe COVID-19 pneumonia. Tocilizumab is designed to calm an overactive immune response, which can cause severe lung damage. The trial compared the drug against a placebo to see if it improved patients' clinical status and reduced their need for oxygen or ventilators over 28 days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Queen's Medical Center
Honolulu, Hawaii, 96813, United States
Conditions
Explore the condition pages connected to this study.